Project Grant R01DK140308
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $410,000.00 to The University of Texas Southwestern Medical Center to study the effects of glucagon-like peptide 1 (GLP-1) receptor agonists and brain-derived GLP-1 on the activity of neuropeptide Y/agouti-related peptide (NPY/AGRP) neurons and their impact on metabolism. The research aims to define the...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,074,199 to the Albert Einstein College of Medicine to conduct research on the top-down regulation of feeding-related behavior. The research aims to define the connectivity between hypothalamus melanocortin peptide expressing neurons and melanocortin 4 receptor (MC4R)-expressing neurons...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $120,792 to the University of Alabama at Birmingham to conduct research assessing the mechanistic relationships between central amygdala neuron activity and glucagon-like peptide-1 receptor agonism. The project aims to pursue a functional analysis of GLP-1 receptors in the control of...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $176,500.00 to the University of Washington to investigate the links between hypothalamic microglia activation and perineuronal net (PNN) loss in the arcuate nucleus, and how these changes contribute to the pathogenesis of diet-induced obesity and glucose regulation. The...
- This Project Grant award of $249,000.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to New York University aims to improve understanding of how hunger and satiety neurons regulate the activity of downstream neurons in the hypothalamus. Specifically, the research will use novel molecular and optical tools to measure and manipulate cyclic AMP (cAMP) signaling in paraventricular hypothalamic neurons that express melanocortin-4 receptors (PVHMC4R), which...
- This Project Grant award, valued at $747,133.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research by the Monell Chemical Senses Center to behaviorally, physiologically, anatomically, and molecularly characterize a population of neurons in the nucleus tractus solitarius (NTS) that express glucagon-like peptide-1 receptors (GLP1R) and...
- This federal Project Grant award of $828,771 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to study the neural mechanisms underlying the metabolic benefits of bariatric surgeries, such as vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB). The key objectives are to employ electrophysiological techniques to analyze changes in neuronal excitability and...
- This $315,342 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Velum Inc., a pharmaceutical research company based in Cambridge, Massachusetts. The grant supports the development of a novel weight loss drug centered on the peptide hormone Peptide YY (PYY). The goal is to create a chimeric triagonist molecule that combines the effects of PYY...
- This $802,363 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund a research study at Emory University from September 2025 to June 2030 to develop models for predicting the benefits of GLP-1 receptor agonist (GLP-1RA) treatments in preventing obesity-related cardiometabolic diseases. The study aims to use clinical...
- This $1,280,753 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) supports research on the role of hypothalamic SH2B1 neurocircuits and SH2B1 signal transduction pathways in obesity and metabolic disease. The research, conducted by the Regents of the University of Michigan, aims to identify SH2B1-expressing neurons in the paraventricular hypothalamus (PVH) that control...
PATHOPHYSIOLOGICAL MECHANISMS IN THE BRAIN'S ENDOGENOUS GLUCAGON-LIKE PEPTIDE 1 SYSTEM MEDIATED BY OBESOGENIC DIETS - TITLE: PATHOPHYSIOLOGICAL MECHANISMS IN THE BRAIN'S ENDOGENOUS GLUCAGON-LIKE PEPTIDE 1 SYSTEM MEDIATED BY OBESOGENIC DIETS PHARMACOTHERAPIES THAT TARGET THE GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1R) SYSTEM ARE COMMONLY PRESCRIBED FOR THE TREATMENT OF TYPE II DIABETES AND, MORE RECENTLY, FOR WEIGHT LOSS. ALTHOUGH SUCCESSFUL AT REDUCING APPETITE AND BODYWEIGHT, THERE ARE SEVERAL LIMITATIONS OF GLP-1R AGONISTS THAT LIMIT THEIR WIDESPREAD USE. MOREOVER, THE ROLE OF THE ENDOGENOUS GLP-1 AND GLP-1R SYSTEM, PARTICULARLY IN THE BRAIN, AND ITS ROLE IN OBESITY PATHOGENESIS IS UNCLEAR. IN THIS APPLICATION, OUR MULTIDISCIPLINARY TEAM WILL ADDRESS THIS PRIMARY GAP IN KNOWLEDGE BY DISSECTING THE FUNCTION AND ACTIVITY STATES OF GLP-1-PRODUCING NEURONS IN THE NUCLEUS OF THE SOLITARY TRACT (NTS) AND THEIR OUTPUTS TO GLP-1R-EXPRESSING NEURONS IN THE PARAVENTRICULAR NUCLEUS OF THE HYPOTHALAMUS (PVH) IN A MODEL OF DIET-INDUCED OBESITY. IN AIM 1, WE WILL USE CONVERGENT ELECTROPHYSIOLOGICAL, ANATOMICAL, AND OPTICAL METHODS TO MEASURE THE WIRING AND ACTIVITY STATES OF GCGNTS NEURONS, THE PRIMARY SOURCE OF GLP-1 IN THE BRAIN, AFTER EXPOSURE TO OBESOGENIC HIGH FAT DIET. FURTHER, WE WILL USE CUSTOM TOOLS AND NOVEL TRANSGENIC MICE TO DISSECT NEUROTRANSMISSION BETWEEN GCGNTS NEURONS AND ONE OF THEIR PRIMARY OUTPUTS IN THE PVH, GLP1RPVH NEURONS, EX VIVO AND IN VIVO. IN AIM 2, WE WILL DETERMINE THE CAUSAL ROLE OF GCGNTS NEURONS AND OUTPUTS TO THE PVH IN PROGRESSIVE AND INTERVENTIONAL MODELS OF DIET-INDUCED OBESITY USING INTERSECTIONAL VIRAL TOOLS. THESE EXCITING EXPERIMENTS WILL YIELD IMPORTANT INSIGHT INTO THE PATHOPHYSIOLOGICAL ROLE OF THE BRAIN'S ENDOGENOUS GLP-1/GLP- 1R SYSTEM AND ESTABLISH IF TARGETING GCGNTS NEURONS IS A THERAPEUTICALLY TRACTABLE STRATEGY FOR NEW OBESITY TREATMENTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $628.3k | 7/16/25 | ||
| Not listed | $656.0k | 8/4/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
000542155SC001AYAS | Vanderbilt University | Project Grant R01DK140308 | $191.2k | 12/19/24 |